Klinik für Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Ludwig-Maximilians-Universität München, Munich, Germany.
J Cancer Res Clin Oncol. 2024 Apr 29;150(4):219. doi: 10.1007/s00432-024-05742-1.
Mistletoe treatment in cancer patients is controversial, and a Cochrane review concluded that due to heterogeneity, performing a meta-analysis was not suitable. However, several systematic reviews included meta-analyses in favor of mistletoe. The aim of this work was to assess the influence of the methodological quality of controlled studies on the results of a meta-analysis regarding overall survival.
Between April and August 2022, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and Web of Science were systematically searched. In addition, reference lists of previously published meta-analyses were checked for relevant publications. A random effects meta-analysis with clustering was performed. The risk of bias within the studies was assessed using ROB 2.0 and ROBINS-I.
The search identified 4685 hits, and 28 publications reporting on 28 298 patients were included in the quantitative analysis. Overall, the analysis led to a significant result in favor of mistletoe therapy (overall HR = 0.61 with 95% CI [0.53;0.7]). According to our subgroup analysis of randomized studies, studies of higher quality (lower risk of bias) did not lead to a significant result in favor of mistletoe therapy (HR = 0.78; CI = [0.30; 2.00]).
In the case of mistletoe therapy, the results of the meta-analysis strongly depended on the methodological quality of the included studies. Calculating meta-analyses that include low-quality studies may lead to severe misinterpretation of the data.
在癌症患者中使用槲寄生治疗存在争议,Cochrane 综述得出结论,由于存在异质性,不适合进行荟萃分析。然而,一些系统评价纳入了支持槲寄生的荟萃分析。本研究旨在评估对照研究方法学质量对总生存荟萃分析结果的影响。
2022 年 4 月至 8 月,系统检索了 Medline、Embase、Cochrane 对照试验中心注册库(CENTRAL)、PsycINFO、CINAHL 和 Web of Science。此外,还检查了先前发表的荟萃分析的参考文献列表,以查找相关出版物。采用随机效应荟萃分析,并进行聚类。使用 ROB 2.0 和 ROBINS-I 评估研究内的偏倚风险。
搜索共确定了 4685 条记录,有 28 项研究报告了 28298 例患者,纳入了定量分析。总体而言,分析结果支持槲寄生治疗(总 HR=0.61,95%CI [0.53;0.7])。根据我们对随机研究的亚组分析,质量较高(偏倚风险较低)的研究并未得出支持槲寄生治疗的显著结果(HR=0.78;CI=[0.30;2.00])。
在槲寄生治疗的情况下,荟萃分析的结果强烈依赖于纳入研究的方法学质量。计算纳入低质量研究的荟萃分析可能会导致对数据的严重误解。